DOCSLIB.ORG

Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus,-Mucor, and -Lichtheimia Species Marisa Z

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus,-Mucor, and -Lichtheimia Species Marisa Z CLINICAL MICROBIOLOGY REVIEWS, Apr. 2011, p. 411–445 Vol. 24, No. 2 0893-8512/11/$12.00 doi:10.1128/CMR.00056-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus,-Mucor, and -Lichtheimia Species Marisa Z. R. Gomes,1,2 Russell E. Lewis,1,3 and Dimitrios P. Kontoyiannis1* Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 770301; Nosocomial Infection Research Laboratory, Instituto Oswaldo Cruz, Fundac¸a˜o Oswaldo Cruz, Rio de Janeiro, Brazil2; and University of Houston College of Pharmacy, Houston, Texas3 INTRODUCTION .......................................................................................................................................................412 TAXONOMIC ORGANIZATION OF UNUSUAL MUCORALES ORGANISMS.............................................412 Downloaded from LITERATURE SEARCH AND CRITERIA .............................................................................................................413 Cunninghamella bertholletiae...................................................................................................................................414 Taxonomy.............................................................................................................................................................414 Reported cases.....................................................................................................................................................414 Epidemiology and risk factors ..........................................................................................................................415 Pathogenesis ........................................................................................................................................................416 Clinical presentation ..........................................................................................................................................417 (i) Disseminated infection .............................................................................................................................417 (ii) Pulmonary infection.................................................................................................................................418 http://cmr.asm.org/ (iii) Cardiovascular involvement ..................................................................................................................418 (iv) Rhino-orbito-cerebral infection .............................................................................................................418 (v) Soft tissue infection..................................................................................................................................419 (vi) Peritonitis .................................................................................................................................................419 (vii) Breakthrough C. bertholletiae infection................................................................................................419 (viii) C. bertholletiae infection in pediatric patients ...................................................................................419 (ix) Chronic infection.....................................................................................................................................419 Diagnosis..............................................................................................................................................................419 Management ........................................................................................................................................................420 Rhizomucor pusillus .................................................................................................................................................421 on November 15, 2018 by guest Taxonomy.............................................................................................................................................................421 Reported cases.....................................................................................................................................................422 Epidemiology .......................................................................................................................................................422 Pathogenesis ........................................................................................................................................................423 Clinical presentation ..........................................................................................................................................423 (i) Pulmonary infection..................................................................................................................................423 (ii) Disseminated infection ............................................................................................................................423 (iii) Soft tissue infections and osteomyelitis...............................................................................................423 (iv) Rhino-orbito-cerebral infection .............................................................................................................424 (v) Cerebral infection .....................................................................................................................................424 (vi) Intra-abdominal infection ......................................................................................................................424 (vii) Chronic and recurrent infections.........................................................................................................424 (viii) Breakthrough infections.......................................................................................................................424 Diagnosis..............................................................................................................................................................424 Management and prognosis ..............................................................................................................................424 Apophysomyces elegans Complex ............................................................................................................................425 Taxonomy.............................................................................................................................................................425 Reported cases and epidemiology.....................................................................................................................425 Pathogenesis ........................................................................................................................................................425 Clinical presentation ..........................................................................................................................................426 (i) Soft tissue infection and osteomyelitis ...................................................................................................426 (ii) Rhino-orbito-cerebral infection..............................................................................................................426 (iii) Disseminated infection...........................................................................................................................426 (iv) Renal infection.........................................................................................................................................427 (v) Intra-abdominal infection........................................................................................................................427 (vi) Subacute or chronic infection................................................................................................................427 * Corresponding author. Mailing address: Department of Infectious Diseases, Infection Control and Employee Health, Unit 1460, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6237. Fax: (713) 745-6839. E-mail: [email protected]. 411 412 GOMES ET AL. CLIN.MICROBIOL.REV. Diagnosis..............................................................................................................................................................427 Management ........................................................................................................................................................427 Prognosis..............................................................................................................................................................428 Saksenaea vasiformis complex ................................................................................................................................428 Taxonomy and reported cases...........................................................................................................................428 Epidemiology .......................................................................................................................................................428 Pathogenesis ........................................................................................................................................................428
Load more

Recommended publications
  • Fungemia and Cutaneous Zygomycosis Due to Mucor
    Jpn. J. Infect. Dis., 62, 146-148, 2009 Short Communication Fungemia and Cutaneous Zygomycosis Due to Mucor circinelloides in an Intensive Care Unit Patient: Case Report and Review of Literature Murat Dizbay, Esra Adisen1, Semra Kustimur2, Nuran Sari, Bulent Cengiz3, Burce Yalcin2, Ayse Kalkanci2*, Ipek Isik Gonul4, and Takashi Sugita5 Department of Infectious Diseases, 1Department of Dermatology, 2Department of Microbiology, 3Department of Neurology, and 4Department of Pathology, Gazi University School of Medicine, Ankara, Turkey, and 5Department of Microbiology, Meiji Pharmaceutical University, Tokyo 204-8588, Japan (Received February 6, 2008. Accepted December 26, 2008) SUMMARY: Mucor spp. are rarely pathogenic in healthy adults, but can cause fatal infections in patients with immuosuppression and diabetes mellitus. Documented mucor fungemia is a very rare condition in the literature. We described a fungemia and cutaneous mucormycosis case due to Mucor circinelloides in an 83-year-old woman with diabetes mellitus who developed acute left frontoparietal infarctus while hospitalized in a neuro- logical intensive care unit. The diagnosis was made based on the growth of fungi in the blood, skin biopsy cultures, and a histopathologic examination of the skin biopsy. The isolates were identified as M. circinelloides by molecular methods. This case is important in that it shows a case of cutaneous mucormycosis which developed after fungemia and provides a contribution to the literature regarding Mucor fungemia. Mucormycosis manifests as a rhinoorbitocerebral, pulmo- not associated with an invasive fungal disease. In addition, nary, gastrointestinal, cutaneous, or disseminated disease. The paranasal sinus and pulmonary computed tomography (CT) most frequently isolated pathogens are Rhizopus, Mucor, results were not indicative of any invasive fungal disease.
    [Show full text]
  • Epidemiological Alert: COVID-19 Associated Mucormycosis
    Epidemiological Alert: COVID-19 associated Mucormycosis 11 June 2021 Given the potential increase in cases of COVID-19 associated mucormycosis (CAM) in the Region of the Americas, the Pan American Health Organization / World Health Organization (PAHO/WHO) recommends that Member States prepare health services in order to minimize morbidity and mortality due to CAM. Introduction In recent months, an increase in reports of cases of Mucormycosis (previously called zygomycosis) is the term used to name invasive fungal infections (IFI) COVID-19 associated Mucormycosis (CAM) has caused by saprophytic environmental fungi, been observed mainly in people with underlying belonging to the subphylum Mucoromycotina, order diseases, such as diabetes mellitus (DM), diabetic Mucorales. Among the most frequent genera are ketoacidosis, or on steroids. In these patients, the Rhizopus and Mucor; and less frequently Lichtheimia, most frequent clinical manifestation is rhino-orbital Saksenaea, Rhizomucor, Apophysomyces, and Cunninghamela (Nucci M, Engelhardt M, Hamed K. mucormycosis, followed by rhino-orbital-cerebral Mucormycosis in South America: A review of 143 mucormycosis, which present as secondary reported cases. Mycoses. 2019 Sep;62(9):730-738. doi: infections and occur after SARS CoV-2 infection. 1,2 10.1111/myc.12958. Epub 2019 Jul 11. PMID: 31192488; PMCID: PMC6852100). Globally, the highest number of cases has been The infection is acquired by the implantation of the reported in India, where it is estimated that there spores of the fungus in the oral, nasal, and are more than 4,000 people with CAM.3 conjunctival mucosa, by inhalation, or by ingestion of contaminated food, since they quickly colonize foods rich in simple carbohydrates.
    [Show full text]
  • Saksenaea Loutrophoriformis Fungal Planet Description Sheets 377
    376 Persoonia – Volume 38, 2017 Saksenaea loutrophoriformis Fungal Planet description sheets 377 Fungal Planet 622 – 20 June 2017 Saksenaea loutrophoriformis D.A. Sutton, Stchigel, Chander, Guarro & Cano, sp. nov. Etymology. From the ancient Greek λουτροφόρος-, and from the Latin Based on a megablast search of NCBIs GenBank nucleotide -forma, because of the vessel-shape of the sporangiophore. database, the closest hit with the ex-type strain using the Classification — Saksenaeaceae, Mucorales, Mucoromy- ITS sequence is Saksenaea vasiformis PWQ2338 (GenBank cotina. KP132601; Identities = 694/739 (94 %), Gaps 27/739 (3 %)); using the LSU sequence it is Saksenaea erythrospora strain Hyphae sparsely septate, branched, hyaline, smooth-walled, UTHSC 06-576 (GenBank HM776683; Identities = 714/735 3–15 μm wide. Sporangiophores erect, generally arising singly, (97 %), Gaps 3/735 (0 %)); and using the EF1-α sequence it is at first hyaline, soon becoming brown, unbranched, 50–75 μm Saksenaea vasiformis strain FMR 10131 (HM776689; Identities long, 5–10 μm wide, slightly verrucose. Sporangia terminal, = 465/477 (97 %), no gaps). Our phylogenetic tree, built from multi-spored, flask-shaped, asperulate, 70–125 μm long, with the ITS, LSU, and EF1-α nucleotide sequences, corroborated a long (60–100 μm) neck; apex of the neck closed with a mu- that our isolates represent a new species, the closest species cilaginous plug. Sporangiospores mostly bacilliform, bilaterally being S. vasiformis, with 93.6 % similarity with respect to the compressed and rounded at both ends, more or less trapezoidal ex-type strain (NRRL 2443). The sporangiospores of S. loutro- in lateral view, smooth-walled, 3.5–6(–7) × 2–3.5 μm, pale olive phoriformis are similar in size to the S.
    [Show full text]
  • Jemds.Com Original Research Article
    Jemds.com Original Research Article PATHOGENIC FUNGAL CONTAMINATION OF MUNICIPAL DUMPING YARD, KOTTAYAM AND RELATED HEALTH EFFECTS Vipinunni1, Bernaitis L2, Sabarianand3, Preesly M. S4, Revathi P. Shenoy5 1Lecturer, RVS Dental College, Coimbatore. 2Lecturer, RVS Dental College, Coimbatore. 3Lecturer, Mahatma Gandhi Medical College, Pondicherry. 4Lecturer, RVS Siddha Medical College & Hospital, Coimbatore. 5Associate Professor, Kasturba Medical College, Manipal. ABSTRACT BACKGROUND Fungi are ubiquitous soil saprophytes often involved in various human ailments. Fungal diseases are emerging worldwide. However, the mycological health risks associated with dumping yard is not much investigated, especially from developing countries where such sites are very common. Aims and Objectives- The major objective of the study was to analyse the possible mycological threat posed by the municipal dumping yard. The study also aims to assess the health status of interacting community in relation to the dumping yard. MATERIALS AND METHODS A descriptive study was conducted from April to June 2015 in Kottayam Municipal dumping yard at Vadavathoor. Two set of soil samples, a total of 50 from the dumping yard were collected, before and after burning of the dumping yard. One set of samples from leachate and neighbouring open wells were collected after burning of the dumping yard. Samples were collected in sterile containers and transported immediately to the laboratory. The samples were cultured on to suitable fungal culture medium and the growths of the fungus were identified by the microscopic and macroscopic features. RESULTS The isolated fungal pathogens from the soil shows that 49% isolates belonged to the Aspergillus genus; and the remaining 51% was almost equally shared by four other different species Geotrichum, Humicola, Microsporum, Rhizopus.
    [Show full text]
  • Saksenaea Vasiformis Causing Cutaneous Zygomycosis: an Experience from Tertiary Care Hospital in Mumbai Microbiology Section Microbiology
    DOI: 10.7860/JCDR/2018/33895.11720 Original Article Saksenaea vasiformis Causing Cutaneous Zygomycosis: An Experience from Tertiary Care Hospital in Mumbai Microbiology Section Microbiology SHASHIR WASUDEORAO WANJARE1, SULMAZ FAYAZ RESHI2, PREETI RAJIV MEHTA3 ABSTRACT was retrieved from medical records department. Diagnosis of Introduction: Zygomycosis, a fungal infection caused by a zygomycosis was based on 10% Potassium Hydroxoide (KOH) group of filamentous fungi, Zygomycetes. Zygomycetes belong examination, culture on Sabouraud’s Dextrose Agar (SDA), to orders Mucorales and Entomorphthorales. Infection occurs identification of fungus by slide culture, Lactophenol Cotton in rhinocerebral, pulmonary, cutaneous, abdominal, pelvic and Blue (LPCB) mount and Water Agar method. disseminated forms. Cutaneous zygomycosis is the third most Results: In the present study, seven cases of cutaneous common presentation, usually occurring as gradual and slowly Zygomycosis caused by emerging pathogen Saksenaea progressive disease but may sometimes become fulminant vasiformis were studied. On analysing these cases, it was found leading to necrotizing lesion and haematogenous dissemination. that break in the skin integrity predisposes to infection. Two Infection caused by Saksenaea vasiformis is rare but are patients were known cases of Diabetes mellitus, while five of emerging pathogens having a tendency to cause infection even them had no underlying associated medical conditions. This in immunocompetent hosts. study shows that although infection with Saksenaea vasiformis Aim: To analyse cases of cutaneous zygomycosis caused is more common in immunocompromised patients but a healthy by Saksenaea vasiformis with respect to risk factors, clinical individuals can be infected and may have a bad prognosis if presentation, causative agents, management and patient diagnosis and treatment is delayed.
    [Show full text]
  • New Species and Changes in Fungal Taxonomy and Nomenclature
    Journal of Fungi Review From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature Nathan P. Wiederhold * and Connie F. C. Gibas Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; [email protected] * Correspondence: [email protected] Received: 29 October 2018; Accepted: 13 December 2018; Published: 16 December 2018 Abstract: Fungal taxonomy is the branch of mycology by which we classify and group fungi based on similarities or differences. Historically, this was done by morphologic characteristics and other phenotypic traits. However, with the advent of the molecular age in mycology, phylogenetic analysis based on DNA sequences has replaced these classic means for grouping related species. This, along with the abandonment of the dual nomenclature system, has led to a marked increase in the number of new species and reclassification of known species. Although these evaluations and changes are necessary to move the field forward, there is concern among medical mycologists that the rapidity by which fungal nomenclature is changing could cause confusion in the clinical literature. Thus, there is a proposal to allow medical mycologists to adopt changes in taxonomy and nomenclature at a slower pace. In this review, changes in the taxonomy and nomenclature of medically relevant fungi will be discussed along with the impact this may have on clinicians and patient care. Specific examples of changes and current controversies will also be given. Keywords: taxonomy; fungal nomenclature; phylogenetics; species complex 1. Introduction Kingdom Fungi is a large and diverse group of organisms for which our knowledge is rapidly expanding.
    [Show full text]
  • TESE Diogo Xavier Lima.Pdf
    UNIVERSIDADE FEDERAL DE PERNAMBUCO CENTRO DE BIOCIÊNCIAS DEPARTAMENTO DE MICOLOGIA PROGRAMA DE PÓS-GRADUAÇÃO EM BIOLOGIA DE FUNGOS DIOGO XAVIER LIMA ASPECTOS ECOLÓGICOS E CARACTERIZAÇÃO ENZIMÁTICA DE MUCORALES DE SOLOS DE MATA ATLÂNTICA DO LITORAL DE PERNAMBUCO, BRASIL Recife 2018 DIOGO XAVIER LIMA ASPECTOS ECOLÓGICOS E CARACTERIZAÇÃO ENZIMÁTICA DE MUCORALES DE SOLOS DE MATA ATLÂNTICA DO LITORAL DE PERNAMBUCO, BRASIL Tese apresentada ao Programa de Pós-Graduação em Biologia de Fungos do Departamento de Micologia do Centro de Ciências Biológicas da Universidade Federal de Pernambuco, como requisito parcial para a obtenção do título de Doutor em Biologia de Fungos. Área de concentração: Taxonomia e Ecologia Orientador: Profa. Dra. Cristina Maria de Souza Motta Co-orientador: Prof. Dr. André Luiz C. M. de A. Santiago Recife 2018 Catalogação na fonte: Bibliotecário Bruno Márcio Gouveia - CRB-4/1788 Lima, Diogo Xavier Aspectos ecológicos e caracterização enzimática de mucorales de solos de mata atlântica do litoral de Pernambuco, Brasil / Diego Xavier Lima. – 2018. 116 f. : il. Orientadora: Cristina Maria de Souza Motta. Coorientador: André Luiz C. M. de A. Santiago. Tese (doutorado) – Universidade Federal de Pernambuco. Centro de Biociências. Programa de Pós-graduação em Biologia de Fungos, Recife, 2018. Inclui referências e anexos. 1. Fungos. 2. Biologia – Classificação. 3. Ecologia. I. Motta, Cristina Maria de Souza (Orientadora). II. Santiago, André Luiz C. M. de A. (coorientador). III. Título. 579.5 CDD (22.ed.) UFPE/CB – 2018 - 140 DIOGO XAVIER LIMA ASPECTOS ECOLÓGICOS E CARACTERIZAÇÃO ENZIMÁTICA DE MUCORALES DE SOLOS DE MATA ATLÂNTICA DO LITORAL DE PERNAMBUCO, BRASIL Tese apresentada ao Programa de Pós-Graduação em Biologia de Fungos do Departamento de Micologia do Centro de Ciências Biológicas da Universidade Federal de Pernambuco, como requisito parcial para a obtenção do título de Doutor em Biologia de Fungos.
    [Show full text]
  • Ep 3323422 A1
    (19) TZZ¥¥ ¥ _T (11) EP 3 323 422 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.05.2018 Bulletin 2018/21 A61K 38/00 (2006.01) C07K 7/08 (2006.01) (21) Application number: 16306539.4 (22) Date of filing: 22.11.2016 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • MARBAN, Céline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 68000 COLMAR (FR) PL PT RO RS SE SI SK SM TR • METZ-BOUTIGUE, Marie-Hélène Designated Extension States: 67000 STRASBOURG (FR) BA ME • LAVALLE, Philippe Designated Validation States: 67370 WINTZENHEIM KOCHERSBERG (FR) MA MD • SCHAAF, Pierre 67120 MOLSHEIM (FR) (71) Applicants: • HAIKEL, Youssef • Université de Strasbourg 67000 STRASBOURG (FR) 67000 Strasbourg (FR) • Institut National de la Santé et de la Recherche (74) Representative: Cabinet Becker et Associés Médicale 25, rue Louis le Grand 75013 Paris (FR) 75002 Paris (FR) (54) NEW D-CONFIGURED CATESLYTIN PEPTIDE (57) The present invention relates to a cateslytin pep- no acids residues of said cateslytin are D-configured. The tide having an amino acid sequence consisting or con- invention also relates to the use of said cateslytin peptide sisting essentially in the sequence of SEQ ID NO: 1, as a drug, especially in the treatment of an infection in a wherein at least 80%, preferably at least 90%, of the ami- patient in needs thereof. EP 3 323 422 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 323 422 A1 Description Field of the Invention 5 [0001] The present invention relates to the field of medicine, in particular of infections.
    [Show full text]
  • A New European Species of the Opportunistic Pathogenic 2 Genus Saksenaea – S
    bioRxiv preprint doi: https://doi.org/10.1101/597955; this version posted April 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A New European Species of The Opportunistic Pathogenic 2 Genus Saksenaea – S. dorisiae Sp. Nov. 3 Roman Labudaa,c*, Andreas Bernreiterb,c, Doris Hochenauerb, Christoph Schüllerb,c, Alena 4 Kubátovád, Joseph Straussb,c and Martin Wagnera,c a 5 Department for Farm Animals and Veterinary Public Health, Institute of Milk Hygiene, Milk Technology and 6 Food Science; Bioactive Microbial Metabolites group (BiMM), University of Veterinary Medicine Vienna, Konrad 7 Lorenz Strasse 24, 3430 Tulln a.d. Donau, Austria 8 bDepartment of Applied Genetics and Cell Biology, Fungal Genetics and Genomics Laboratory, University of 9 Natural Resources and Life Sciences, Vienna (BOKU); Konrad Lorenz Strasse 24, 3430 Tulln a.d. Donau, Austria 10 c Research Platform Bioactive Microbial Metabolites (BiMM), Konrad Lorenz Strasse 24, 3430 Tulln a.d. Donau, 11 Austria 12 d Charles University, Faculty of Science, Department of Botany, Culture Collection of Fungi (CCF), Benátská 2, 13 128 01 Prague 2, Czech Republic 14 15 *Corresponding author. Email: [email protected] 16 17 1 bioRxiv preprint doi: https://doi.org/10.1101/597955; this version posted April 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract: A new species Saksenaea dorisiae (Mucoromycotina, Mucorales), recently isolated 19 from a water sample originating from a private well in a rural area of Serbia (Europe), is 20 described and illustrated.
    [Show full text]
  • Biology, Systematics and Clinical Manifestations of Zygomycota Infections
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IBB PAS Repository Biology, systematics and clinical manifestations of Zygomycota infections Anna Muszewska*1, Julia Pawlowska2 and Paweł Krzyściak3 1 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawiskiego 5a, 02-106 Warsaw, Poland; [email protected], [email protected], tel.: +48 22 659 70 72, +48 22 592 57 61, fax: +48 22 592 21 90 2 Department of Plant Systematics and Geography, University of Warsaw, Al. Ujazdowskie 4, 00-478 Warsaw, Poland 3 Department of Mycology Chair of Microbiology Jagiellonian University Medical College 18 Czysta Str, PL 31-121 Krakow, Poland * to whom correspondence should be addressed Abstract Fungi cause opportunistic, nosocomial, and community-acquired infections. Among fungal infections (mycoses) zygomycoses are exceptionally severe with mortality rate exceeding 50%. Immunocompromised hosts, transplant recipients, diabetic patients with uncontrolled keto-acidosis, high iron serum levels are at risk. Zygomycota are capable of infecting hosts immune to other filamentous fungi. The infection follows often a progressive pattern, with angioinvasion and metastases. Moreover, current antifungal therapy has often an unfavorable outcome. Zygomycota are resistant to some of the routinely used antifungals among them azoles (except posaconazole) and echinocandins. The typical treatment consists of surgical debridement of the infected tissues accompanied with amphotericin B administration. The latter has strong nephrotoxic side effects which make it not suitable for prophylaxis. Delayed administration of amphotericin and excision of mycelium containing tissues worsens survival prognoses. More than 30 species of Zygomycota are involved in human infections, among them Mucorales are the most abundant.
    [Show full text]
  • Mucormycosis: Botanical Insights Into the Major Causative Agents
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Mucormycosis: Botanical Insights Into The Major Causative Agents Naser A. Anjum Department of Botany, Aligarh Muslim University, Aligarh-202002 (India). e-mail: [email protected]; [email protected]; [email protected] SCOPUS Author ID: 23097123400 https://www.scopus.com/authid/detail.uri?authorId=23097123400 © 2021 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Abstract Mucormycosis (previously called zygomycosis or phycomycosis), an aggressive, liFe-threatening infection is further aggravating the human health-impact of the devastating COVID-19 pandemic. Additionally, a great deal of mostly misleading discussion is Focused also on the aggravation of the COVID-19 accrued impacts due to the white and yellow Fungal diseases. In addition to the knowledge of important risk factors, modes of spread, pathogenesis and host deFences, a critical discussion on the botanical insights into the main causative agents of mucormycosis in the current context is very imperative. Given above, in this paper: (i) general background of the mucormycosis and COVID-19 is briefly presented; (ii) overview oF Fungi is presented, the major beneficial and harmFul fungi are highlighted; and also the major ways of Fungal infections such as mycosis, mycotoxicosis, and mycetismus are enlightened; (iii) the major causative agents of mucormycosis
    [Show full text]
  • Meeting Programme All Sessions Will Take Place in the Brueton Room, Park Suite Posters Will Be Displayed in the Malvern Room, Park Suite
    53rd BSMM Annual Scientific Meeting St John’s Hotel, Solihull, Birmingham March 19th -21st 2017 Meeting Programme All sessions will take place in the Brueton Room, Park Suite Posters will be displayed in the Malvern Room, Park Suite SUNDAY 19TH MARCH 2017 From 13.30 Registration (Park Suite Entrance) 14.00 -16.00 BSMM Executive Committee Meeting (Room tbc) (BSMM Executive Only) 14.30 – 16.30 WTSA Early Careers Workshop (Open to all) Chaired by Simon Johnston (University of Sheffield) Tanya Roberts (Senior Medical Scientist, Gilead), Tim Dafforn (Chief Entrepreneurial Advisor, BEIS, UK Government) Georgina Drury (Research Support Partner, University of Birmingham) Sheba Agarwal-Jans, (Journal Publisher, Elsevier), David Brown (Biosciences Technical Lead, Health & Safety Executive) Tehmina Amin (Project Administrator, Wellcome Trust Strategic Award) Andy Borman (Principal Clinical Scientist, Public Health England) SESSION ONE CHAIR: LEWIS WHITE (PUBLIC HEALTH WALES) 16.45 Official Welcome 17.00 Poster Elevator Talks (6 x 5min slots) Leenah Alaalm, Jagdish Chander, Kangzhen Dong, Robert Evans, Mariam Garelnabi, Jemima Ho 17.30 BSMM Foundation Lecture, Gordon Brown (MRC Centre for Medical Mycology, Aberdeen) Chaired by Tom Rogers (Trinity College Dublin) 18.30 Poster Session 1 19.30 Dinner & Late Bar MONDAY 20TH MARCH 2017 SESSION TWO CHAIR: GORDON RAMAGE (DENTAL SCHOOL, GLASGOW) 09.00 Keynote 1: Jessica Quintin (Institut Pasteur, Paris) 09.30 Offered Talk 1: Josie Gibson Cryptococcus neoformans expansion in in vivo infection and the role
    [Show full text]